ES2261657T3 - Derivados de hidrazida del acido pirrolidin-2-carboxilico para uso como inhibidores de metaloproteasa. - Google Patents

Derivados de hidrazida del acido pirrolidin-2-carboxilico para uso como inhibidores de metaloproteasa.

Info

Publication number
ES2261657T3
ES2261657T3 ES02719751T ES02719751T ES2261657T3 ES 2261657 T3 ES2261657 T3 ES 2261657T3 ES 02719751 T ES02719751 T ES 02719751T ES 02719751 T ES02719751 T ES 02719751T ES 2261657 T3 ES2261657 T3 ES 2261657T3
Authority
ES
Spain
Prior art keywords
methyl
trifluomethyl
bis
tolyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02719751T
Other languages
English (en)
Spanish (es)
Inventor
Susanne Buser
Anthony P. D. W. Ford
Torsten Hoffmann
Barbara Lenz
Andrew John Sleight
Pierre Vankan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2261657T3 publication Critical patent/ES2261657T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES02719751T 2001-04-23 2002-02-02 Derivados de hidrazida del acido pirrolidin-2-carboxilico para uso como inhibidores de metaloproteasa. Expired - Lifetime ES2261657T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23
EP01109853 2001-04-23

Publications (1)

Publication Number Publication Date
ES2261657T3 true ES2261657T3 (es) 2006-11-16

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02719751T Expired - Lifetime ES2261657T3 (es) 2001-04-23 2002-02-02 Derivados de hidrazida del acido pirrolidin-2-carboxilico para uso como inhibidores de metaloproteasa.

Country Status (17)

Country Link
US (1) US20030004157A1 (https=)
EP (1) EP1385577B1 (https=)
JP (1) JP4146730B2 (https=)
KR (1) KR100599134B1 (https=)
CN (1) CN100398106C (https=)
AR (1) AR035935A1 (https=)
AT (1) ATE323531T1 (https=)
AU (1) AU2002250876B2 (https=)
BR (1) BR0209151A (https=)
CA (1) CA2444395C (https=)
DE (1) DE60210760T2 (https=)
DK (1) DK1385577T3 (https=)
ES (1) ES2261657T3 (https=)
MX (1) MXPA03009720A (https=)
PT (1) PT1385577E (https=)
WO (1) WO2002085458A2 (https=)
ZA (1) ZA200308110B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002259147A1 (en) * 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
ATE366576T1 (de) * 2003-01-31 2007-08-15 Hoffmann La Roche Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-
SI1643998T1 (sl) * 2003-07-03 2007-12-31 Hoffmann La Roche Dvojni nk1/nk3 antagonisti za zdravljenje shizofrenije
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
CN1984891B (zh) 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CN104447716A (zh) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
MX365732B (es) 2007-12-07 2019-06-12 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
WO2010106988A1 (ja) 2009-03-17 2010-09-23 第一三共株式会社 アミド誘導体
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
US20120196901A1 (en) * 2009-10-29 2012-08-02 Merck Sharp & Dohme Corp. Tertiary amide orexin receptor antagonists
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
RU2673084C2 (ru) 2013-11-08 2018-11-22 Киссеи Фармасьютикал Ко., Лтд. Производное карбоксиметилпиперидина
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
AU2019215801B2 (en) * 2018-02-02 2024-09-19 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Parenteral formulations and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
IL134155A0 (en) * 1997-08-06 2001-04-30 Lilly Co Eli 2-acylaminopropanamines as tachykinin receptor antagonists
CN1272842A (zh) * 1997-08-06 2000-11-08 伊莱利利公司 作为速激肽受体拮抗剂的2－酰氨基丙胺类化合物
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
EP1394150B1 (en) * 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
WO2000067742A2 (en) * 1999-05-05 2000-11-16 Warner-Lambert Company Use of gaba analogues for the modulation of substance p
PT1303490E (pt) * 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
ZA200308110B (en) 2005-03-30
CA2444395C (en) 2010-12-21
WO2002085458A2 (en) 2002-10-31
JP2004529931A (ja) 2004-09-30
AR035935A1 (es) 2004-07-28
JP4146730B2 (ja) 2008-09-10
DE60210760T2 (de) 2006-11-23
MXPA03009720A (es) 2004-01-29
DK1385577T3 (da) 2006-08-21
CA2444395A1 (en) 2002-10-31
US20030004157A1 (en) 2003-01-02
ATE323531T1 (de) 2006-05-15
PT1385577E (pt) 2006-08-31
DE60210760D1 (de) 2006-05-24
KR100599134B1 (ko) 2006-07-12
BR0209151A (pt) 2004-07-13
CN1503684A (zh) 2004-06-09
EP1385577A2 (en) 2004-02-04
AU2002250876B2 (en) 2005-03-03
KR20040007503A (ko) 2004-01-24
CN100398106C (zh) 2008-07-02
WO2002085458A3 (en) 2003-10-30
EP1385577B1 (en) 2006-04-19

Similar Documents

Publication Publication Date Title
ES2261657T3 (es) Derivados de hidrazida del acido pirrolidin-2-carboxilico para uso como inhibidores de metaloproteasa.
JP6027662B2 (ja) 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤
CA2451566C (en) Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury
AU2002250876A1 (en) Use of NK-1 receptor antagonists against benign prostatic hyperplasia
SK61399A3 (en) HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa
BRPI0414130B1 (pt) Compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem
AU2002328837A1 (en) Use of NK-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury
TW200817352A (en) Compounds
BRPI0408466B1 (pt) composição farmacêutica e uso de inibidor de proteína de transferência de colesteril éster e crospovidona
EP2351749A1 (en) Carbamate compound or salt thereof
WO2006098394A1 (ja) 脂質吸収抑制方法および脂質吸収抑制剤
ES2324209T3 (es) 2-(3,5-bis-trifluormetil-fenil)-n-(6-(1,1-dioxo-1lambda6-tiomorfolin-4-il)-4-(2-metil o 4-fluor-2-metil substituido)fenil-piridin-3-il)-n-metil-isobutiramida.
TW200922584A (en) Organic compounds
PT95978B (pt) Processo para de novos derivados do 6-aril-5,6-dihidroimidazo/2,l-b/-tiazol comefeito imuno-estimulante
BR112021004893A2 (pt) composições compreendendo um inibidor de crac e um corticosteroide e métodos de uso dos mesmos
EP1289945B1 (en) Aniline disulfide derivatives for treating allergic diseases
ZA200208838B (en) Composition containing a benzamide disulfide derivative for treating allergic diseases.
HK1050677B (en) Aniline disulfide derivatives for treating allergic diseases